Restenosis and gene therapy

Bibliography

• DANGAS G, FUSTER V: Management of restenosis after coronary intervention. Am. HeartJ (1996) 132:428–436.
   PubMed Web of Science ®Google Scholar
• MCBRIDE W, LANGE RA, HILLIS LD: Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl. J. Med. (1988) 318:1734–1737.
   PubMed Web of Science ®Google Scholar
• POPMA JJ, CALIFF RM, TOPOL EJ: Clinical trials of restenosis after coronary angioplasty. Circulation (1991) 84:1426–1436.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF et al.: Randomised trial of coronary intervention with antibody against plateletintegrin for reduction of clinicalrestenosis: results at six months. The EPIC Investiga-tors. Lancet (1994) 343:881–886.
   PubMed Web of Science ®Google Scholar
• ••First report of a beneficial effect of antiplatelet therapy forrestenosis.
   Google Scholar
• MARESTA A, BALDUCELLI M, CANTINI L et al.: Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio
   Google Scholar
• Trapidil versus Aspirin nella Restenosi Coronarica. Circulation (1994) 90:2710–2715.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, COTE G, LESPERANCE J et al.: Probucol andmultivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl. J. Med. (1997) 337:365–372.
   PubMed Web of Science ®Google Scholar
• RAIZNER AE, OESTERLE SN, WAKSMAN R et al.: Inhibitionof Restenosis With I3-Emitting Radiotherapy :Report of the proliferation reduction with vascular energy trial (PREVENT). Circulation (2000) 102:951–958.
   PubMed Web of Science ®Google Scholar
• •A recent report about the use of radiotherapy to prevent restenosis.
   Google Scholar
• VERIN V: Endoluminal beta-irradiation for reduction ofrestenosis following coronary angioplasty. Results of a prospective, randomized, multicenter European dose-finding study. J. Submicrosc. Cytol. Pathol (2000). 32:390 (Abstract).
   Google Scholar
• FISCHMAN DL, LEON MB, BAIM DS et al.: A randomizedcomparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl. J. Med. (1994) 331:496–501.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al.: A comparison of balloon-expandable-stent implanta-tion with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl. J. Med. (1994) 331:489–495.
   PubMed Web of Science ®Google Scholar
• BAEK S, MARCH KL: Gene therapy for restenosis : getting nearer the heart of the matter. Circ. Res. (1998) 82:295–305.
   PubMed Web of Science ®Google Scholar
• DEYOUNG MB, DICHEK DA: Gene therapy for restenosis: are we ready? Circ. Res. (1998) 82:306–313.
   Google Scholar
• ••A counterpoint concerning the feasibility of gene transfer inman to prevent restenosis. KIBBE MR, BILLIAR TR, TZENG E: Gene therapy for restenosis. Circ. Res. (2000) 86:829-833. An overview of potential target genes to prevent restenosis. GUZMAN RJ, HIRSCHOWITZ EA, BRODY SL, CRYSTAL RG, EPSTEIN SE, FINKEL T: In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA (1994) 91:10732–10736.
   Google Scholar
• KIBBE MR, BILLIAR TR, TZENG E: Gene therapy for restenosis. Circ. Res. (2000) 86:829–833.
   PubMed Web of Science ®Google Scholar
• •• An overview of potential target genes to prevent restenosis.
   Google Scholar
• GUZMAN RJ, HIRSCHOWITZ EA, BRODY SL, CRYSTAL RG, EPSTEIN SE, FINKEL T: In vivo suppression of injuryinduced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. USA (1994) 91:10732–10736.
   PubMed Web of Science ®Google Scholar
• HARRELL RL, RAJANAYAGAM MAS, DOANES AM et al.: Inhibition of vascular smooth muscle cell prolifera-tion and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circula-tion (1997) 96:621–627.
   PubMed Web of Science ®Google Scholar
• YONEMITSU Y, KANEDA Y, TANAKA S et al.: Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ. Res. (1998) 82:147–156.
   PubMed Web of Science ®Google Scholar
• SCHEINMAN M, ASCHER E, LEVI GS, HINGORANI A, SHIRAZIAN D, SETH P: p53 gene transfer to the injured rat carotid artery decreases neointimal formation. J Vasc. Surg. (1999) 29:360–369.
   PubMed Web of Science ®Google Scholar
• LUO Z, SATA M, NGUYEN T, KAPLAN JM, AKITA GY, WALSH K: Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation (1999) 99:1776–1779.
   PubMed Web of Science ®Google Scholar
• NOISEUX N, BOUCHER CH, CARTIER R, SIROIS MG: Bolus en dovascular PDGFR-I3 an tisense treatment suppressed intimal hyperplasia in a rat carotid injury model. Circulation (2000) 102:1330–1336.
   PubMed Web of Science ®Google Scholar
• WALSH K, SMITH RC, KIM HS: Vascular cell apoptosis in remodeling, restenosis and plaque rupture. Circ. Res. (2000) 87:184–188.
   PubMed Web of Science ®Google Scholar
• •A recent review of the role of apoptosis in the physiopa-thology of vascular wall.
   Google Scholar
• CHANG MW, BARR E, SELTZER J et al.: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (1995) 267:518–522.
   PubMed Web of Science ®Google Scholar
• CHEN D, KRASINSKI K, SYLVESTER A, CHEN J, NISEN PD, ANDRES V: Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. (1997) 99:2334–2341.
   PubMed Web of Science ®Google Scholar
• YANG ZY, SIMARI RD, PERKINS ND et al.: Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Nati Acad. Sci. USA (1996) 93:7905–7910.
   PubMed Web of Science ®Google Scholar
• GOMEZ J, MARTINEZ A, GONZALEZ A, REBOLLO A: Dual role of Ras and Rho proteins: at the cutting edge of life and death. Immunol. Cell Biol. (1998) 76:125–134.
   PubMed Web of Science ®Google Scholar
• UENO H, YAMAMOTO H, ITO SI, LI JJ, TAKESHITA A: Adenovirus-mediated transfer of a dominant-negative h-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler. Thromb. Vasc. Biol. (1997) 17:898–904.
   PubMed Web of Science ®Google Scholar
• IACCARINO G, SMITHWICK LA, LEFKOWITZ RJ, KOCH WJ: Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc. Natl. Acad. Sci. USA (1999) 96:3945–3950.
   PubMed Web of Science ®Google Scholar
• AUTIERI MV, YUE TL, FERSTEIN GZ, OHLSTEIN E: Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem. Biophys. Res. Commun. (1995) 213:827–836.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, HORIUCHI M et al.: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle prolifera-tion in vivo. Proc. Natl. Acad. Sci. USA (1995) 92:5855–5859.
   PubMed Web of Science ®Google Scholar
• SMITH RC, BRANELLEC D, GORSKI DH et al.: p21 CIP1-mediated inhibition of cell proliferation by overex-pression of the gax homeodomain gene. Genes Dev. (1997) 11:1674–1689.
   PubMed Web of Science ®Google Scholar
• MAILLARD L, VAN BELLE E, SMITH RC etal.: Percutaneousdelivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc. Res. (1997) 35:536–546.
   Google Scholar
• MANO T, LUO Z, MALENDOWICZ SL, EVANS T, WALSH K:Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ. Res. (1999) 84:647–654.
   PubMed Web of Science ®Google Scholar
• NABEL EG, SHUM L, POMPILI VJ et al.: Direct transfer oftransforming growth factor 131 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. ScL USA (1993) 90:10759–10763.
   PubMed Web of Science ®Google Scholar
• HANNA AK, FOX JC, NESCHIS DG, SAFFORD SD, SWAIN JL, GOLDEN MA: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. j Vasc. Stag. (1997) 25:320–325.
   PubMed Web of Science ®Google Scholar
• SIROIS MG, SIMONS M, EDELMAN ER: Antisense oligonu-cleotide inhibition of pdgfr-I3 receptor subunit expres-sion directs suppression of intimal thickening. Circulation (1997) 95:669–676.
   PubMed Web of Science ®Google Scholar
• DEGUCHI J, NAMBA T, HAMADA H et al.: Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Ther. (1999) 6:956–965.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, MORISHITA R, TOMITA N et al.: Against transforming growth factor-I3 inhibited neointimal formation after vascular injury in rat model :potential application of ribozyme strategy to treat cardiovas-cular disease. Circulation (2000) 102:1308–1314.
   PubMed Web of Science ®Google Scholar
• •A recent report concerning the use of a novel approach, the use of ribozyme oligonucleotide, to treat restenosis.
   Google Scholar
• ENGELSE MA, LARDENOYE JH, NEELE JM, PANNEKOEK H,QUAX PH, DE VRIES CJ: Activin, a TGF-beta-like factor, inhibits neointima formation in vitro and in vivo. J. Submicrosc. Cytol. Pathol. (2000). 32:465 (Abstract).
   Google Scholar
• STEPHAN D, SAN H, YANG ZY et al.: Inhibition ofvascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of I3-interferon. Mol Med. (1997) 3:593–599.
   PubMed Web of Science ®Google Scholar
• NEUVILLE P, LARUELLE L, CAMENZIND E et al.:Interferon-beta, a potential therapeutic gene for in-stent restenosis. j Submicrosc. Cytol. Pathol. (2000). 32:466. Abstract.
   Google Scholar
• SHI Y, O& BRIEN JE, FARD A, MANNION JD, WANG D,ZALEWSKI A: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation (1996) 94:1655–1664.
   PubMed Web of Science ®Google Scholar
• SHI Y, PIENIEK M, FARD A, O'BRIEN J, MANNION JD, ZALEWSKI A: Adventitial remodeling after coronary arterial injury. Circulation (1996) 93:340–348.
   PubMed Web of Science ®Google Scholar
• PATEL S, SHI Y, NICULESCU R, CHUNG EH, MARTIN JL, ZALEWSKI A: Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation (2000) 101:524–532.
   PubMed Web of Science ®Google Scholar
• MANDRIOTA SJ, SEGHEZZI G, VASSALLI JD et al: Vascularendothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. (1995) 270:9709–9716.
   PubMed Web of Science ®Google Scholar
• BENDECK MP, ZEMPO N, CLOWES AW, GALARDY RE, REIDY MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. (1994) 75:539–545.
   PubMed Web of Science ®Google Scholar
• ROUIS M, ADAMY C, DUVERGER N et al.: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation (1999) 100:533–540.
   PubMed Web of Science ®Google Scholar
• WILENSKY RL, TANGUAY JF, ITO S et al.: Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am. Heart J. (2000) 139:1061–1070.
   PubMed Web of Science ®Google Scholar
• DICHEK DA, ANDERSON J, KELLY AB, HANSON SR, HARKER LA: Enhanced in vivoantithrombotic effects of endothelial cells expressing recombinant plasmi-nogen activators transduced with retroviral vectors. Circulation (1996) 93:301–309.
   PubMed Web of Science ®Google Scholar
• DICHEK DA, NEVILLE RF, ZWIEBEL JA, FREEMAN SM, LEON MB, ANDERSON WF: Seeding of intravascular stents with genetically engineered endothelial cells. Circulation (1989) 80:1347–1353.
   PubMed Web of Science ®Google Scholar
• •Placement of stents coated with genetically engineered endothelial cells.
   Google Scholar
• DUNN PF, NEWMAN KD, JONES M et al.: Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation (1996) 93:1439–1446.
   Google Scholar
• KIBBE M, BILLIAR T, TZENG E: Gene therapy and vascular disease. Adv. Pharmacol. (1999) 46:85–150.
   PubMedGoogle Scholar
• DER LEYEN HE, GIBBONS GH, MORISHITA R et al.: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. ScL USA (1995) 92:1137–1141.
   PubMed Web of Science ®Google Scholar
• CHEN L, DAUM G, FOROUGH R, CLOWES M, WALTER U, CLOWES AW: Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ. Res. (1998) 82:862–870.
   PubMed Web of Science ®Google Scholar
• JANSSENS S, FLAHERTY D, NONG Z et al.: Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation (1998) 97:1274–1281.
   PubMed Web of Science ®Google Scholar
• VARENNE 0, PISLARU S, GILLIJNS H et al.: Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation (1998) 98:919–926.
   Google Scholar
• SHEARS LL, KIBBE MR, MURDOCK AD et al.: Efficientinhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J. Am. Coll. Surg. (1998) 187:295–306.
   PubMed Web of Science ®Google Scholar
• HOLVOET P, VANHAECKE J, JANSSENS S, VAN DE WF, COLLEN D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circula-tion (1998) 98:1487–1494.
   PubMed Web of Science ®Google Scholar
• HOLVOET P: Endothelial dysfunction, oxidation of low-density lipoprotein and cardiovascular disease. Ther. Apher. (1999) 3:287–293.
   PubMedGoogle Scholar
• HOLVOET P, VAN CLEEMPUT J, COLLEN D, VANHAECKE J: Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. (2000) 20:698–702.
   PubMed Web of Science ®Google Scholar
• DE GEEST B, STENGEL D, LANDELOOS M et al.: Effect of overexpression of human Apo A-I in C57B1/6 and C57B1/6 Apo E-Deficient Mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetyl-hydrolase and paraoxonase: comparison of adenovirus-mediated human Apo A-I gene transfer and human Apo A-I transgenesis. Arterioscler. Thromb. Vasc. Biol. (2000) 20:68–75.
   PubMed Web of Science ®Google Scholar
• DE GEEST B, ZHAO Z, COLLEN D, HOLVOET P: Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation (1997) 96:4349–4356.
   PubMed Web of Science ®Google Scholar
• •A report about the anti-oxidant strategy to prevent neointima formation in mice.
   Google Scholar
• THEILMEIER G, DE GEEST B, VAN VELDHOVEN P et al.: HDL-associated PAF-AfIreduces endothelial adhesive-ness in apoE-/- mice. FASEB (2000) 14:2032–2039.
   Google Scholar
• QUARCK R, DE GEEST B, STENGEL D, COLLEN D, NINIO E, HOLVOET P: Adenovirus-mediated gene transfer of human PAF-acetylhydrolase inhibits neointima formation in apoE-deficient mice. J Submicrosc. Cytol. Pathol. (2000) 32:467 (Abstract).
   Google Scholar
• ASAHARA T, BAUTERS C, PASTORE C etal.: local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates in timal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 91 :2793–2801.
   Google Scholar
• ASAHARA T, CHEN D, TSURUMI Y et al.: Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation (1996) 94:3291–3302.
   PubMed Web of Science ®Google Scholar
• LAITINEN M, ZACHARY I, BREIER G et al.: VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum. Gene Ther. (1997) 8:1737–1744.
   PubMed Web of Science ®Google Scholar
• VAN BELLE E, TIO FO, CHEN D et al.: Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J. Am. Coll. Cardiol. (1997) 29:1371–1379.
   PubMed Web of Science ®Google Scholar
• •Combination of stent seeding and gene therapy to prevent restenosis.
   Google Scholar
• ISNER JM, PIECZEK A, SCHAINFELD R et al.: Clinicalevidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet (1996) 348:370–374.
   PubMed Web of Science ®Google Scholar
• ISNER JM, WALSH K, ROSENFIELD K et al.: Arterial genetherapy for restenosis. Hum. Gene Ther. (1996) 7:989–1011.
   PubMed Web of Science ®Google Scholar
• LAITINEN M, HARTIKAINEN J, HILTUNEN MO et al.: Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. (2000) 11:263–270.
   PubMed Web of Science ®Google Scholar
• LAZAROUS DF, SHOU M, SCHEINOWITZ M et al.: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation (1996) 94:1074–1082.
   PubMed Web of Science ®Google Scholar
• YONEMITSU Y, KANEDA Y, MORISHITA R, NAKAGAWA K, NAKASHIMA Y, SUEISHI K: Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab. Invest. (1996) 75:313–323.
   PubMed Web of Science ®Google Scholar
• KREUZER J, DENGER S, REIFERS F et al.: Adenovirus-assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells. Atherosclerosis (1996) 124:49–60.
   PubMed Web of Science ®Google Scholar
• KUPFER JM, RUAN XM, LIU G, MATLOFF J, FORRESTER J, CHAUX A: High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum. Gene Ther. (1994) 5:1437–1443.
   PubMed Web of Science ®Google Scholar
• DZAU VJ, MANN MJ, MORISHITA R, KANEDA Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl. Acad. Sci. USA (1996) 93:11421–11425.
   PubMed Web of Science ®Google Scholar
• LIU ML, WINTHER BL, KAY MA: Pseudotransduction ofhepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J. Virol. (1996) 70:2497–2502.
   PubMed Web of Science ®Google Scholar
• ORY DS, NEUGEBOREN BA, MULLIGAN RC: A stable human-derived packaging cell line for production of high titer retrovirushesicular stomatitis virus G pseudotypes. Proc. Nati Acad. Sci. USA (1996) 93:11400–11406.
   PubMed Web of Science ®Google Scholar
• YANG Y, VANIN EF, WHITT MA et al.: Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. (1995) 6:1203–1213.
   PubMed Web of Science ®Google Scholar
• LEE SW, TRAPNELL BC, RADE JJ, VIRMANI R, DICHEK DA: In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ. Res. (1993) 73:797–807.
   PubMed Web of Science ®Google Scholar
• LEMARCHAND P, JONES M, YAMADA I, CRYSTAL RG: Invivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ. Res. (1993) 72:1132–1138.
   Google Scholar
• FLUGELMAN MY, JAKLITSCH MT, NEWMAN KD, CASSCELLS W, BRATTHAUER GL, DICHEK DA: LCIAV level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation (1992) 85:1110–1117.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, LITZKY L, WILSON JM: Prolonged transgene expression in cotton rat lung with recombi-nant adenoviruses defective in F2a. Hum. Gene Ther. (1994) 5:1217–1229.
   PubMed Web of Science ®Google Scholar
• GORZIGLIA MI, KADAN MJ, YEI S et al.: Elimination of both El and E2 from adenovirus vectors further improves prospects for in vivohuman gene therapy. J. Vim]. (1996) 70:4173–4178.
   Web of Science ®Google Scholar
• BROUGH DE, LIZONOVA A, HSU C, KULESA VA, KOVESDI I: A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions Fl and E4. j Virol. (1996) 70:6497–6501.
   PubMed Web of Science ®Google Scholar
• GAO GP, YANG Y, WILSON JM: Biology of adenovirus vectors with Fl and E4 deletions for liver- directed gene therapy. J. Virol. (1996) 70:8934–8943.
   PubMed Web of Science ®Google Scholar
• KOCHANEK S, CLEMENS PR, MITANI K, CHEN HH, CHAN S, CASKEY CT: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA (1996) 93:5731–5736.
   PubMed Web of Science ®Google Scholar
• ••Development of a new adenoviral vector that has all viralcoding sequences removed.
   Google Scholar
• FRANZ WM, ROTHMANN T, FREY N, KATUS HA: Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc. Res. (1997) 35:560–566.
   PubMed Web of Science ®Google Scholar
• •Use of tissue-specific promoters to target adenovirus-mediated gene delivery.
   Google Scholar
• NGUYEN T, MANO T, WILLIS K: Targeted suppression of smooth muscle cell proliferation using adenovirus mediated delivery of an Rb-F2Fhybrid gene expressed from the smooth muscle actin promotor. Circulation (1998) 98:1670 (Abstract).
   Google Scholar
• WICKHAM TJ, SEGAL DM, ROELVINK PW et al.: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Vim/. (1996) 70:6831–6838.
   Web of Science ®Google Scholar
• DUAN D, FISHER KJ, BURDA JF, ENGELHARDT JF: Structural and functional heterogeneity of integrated recombinant AAV genomes. Virus Res. (1997) 48:41–56.
   PubMed Web of Science ®Google Scholar
• KESSLER PD, PODSAKOFF GM, CHEN X et al.: Gene delivery to skeletal muscle results in sustained expres-sion and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA (1996) 93:14082–14087.
   PubMed Web of Science ®Google Scholar
• SIMONS M: Endogenous expression modification: antisense approaches. In: Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. March KL (Ed.), Kluwer Academic Publishers, Boston, Mass; Dordrecht, Netherlands; London, UK (1997):143–175.
   Google Scholar
• MANN MJ: E2F decoy oligonucleotide for geneticengineering of vascular bypass grafts. Antisense Nucleic Acid Drug Dev. (1998) 8:171–176.
   PubMedGoogle Scholar
• FRIMERMAN A, WELCH PJ, JIN X et al.: ChimericDNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation (1999) 99:697–703.
   PubMed Web of Science ®Google Scholar
• GOLDMAN B, BLANKE H, WOLINSKY H: Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. A new catheter approach. Atherosclerosis (1987) 65:215–225.
   PubMed Web of Science ®Google Scholar
• NABEL EG, PLAUTZ G, NABEL GJ: Site-specific geneexpression in vivo by direct gene transfer into the arterial wall. Science (1990) 249:1285–1288.
   PubMed Web of Science ®Google Scholar
• NABEL EG, PLAUTZ G, BOYCE FM, STANLEY JC, NABELGJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 244:1342–1344.
   PubMed Web of Science ®Google Scholar
• OHNO T, GORDON D, SAN H et al.: Gene therapy forvascular smooth muscle cell proliferation after arterial injury. Science (1994) 265:781–784.
   PubMed Web of Science ®Google Scholar
• LANDAU C, PIRWITZ MJ, WILLARD MA, GERARD RD, MEIDELL RS, WILLARD SE: Adenoviral mediated gene transfer to atherosclerotic arteries after balloon angioplasty. Am. Heart J. (1995) 129:1051–1057.
   PubMed Web of Science ®Google Scholar
• TAHLIL 0, BRAMI M, FELDMAN LJ, BRANELLEC D, STEGPG: The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc. Res. (1997) 33:181–187.
   PubMed Web of Science ®Google Scholar
• RIESSEN R, RAHIMIZADEH H, BLESSING E, TAKESHITA S, BARRY JJ, ISNER JM: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum. Gene Ther. (1993) 4:749–758.
   PubMed Web of Science ®Google Scholar
• STEG PG, FELDMAN LJ, SCOAZEC JY et al.: Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation (1994) 90:1648–1656.
   PubMed Web of Science ®Google Scholar
• WOLINSKY H, THUNG SN: Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J. Am. Coll Cardiol. (1990) 15:475–481.
   PubMed Web of Science ®Google Scholar
• BARATH P, POPOV A, MICHIELS R: Nipple balloon catheter. Semin. Intervent. Cardiol (1996) 1:43.
   PubMedGoogle Scholar
• FERNANDEZ-ORTIZ A, MEYER BJ, MAILHAC A et al.: A new approach for local intravascular drug delivery. Iontophoretic balloon. Circulation (1994) 89:1518–1522.
   PubMed Web of Science ®Google Scholar
• GONSCHIOR P, PAHL C, HUEHNS TY et al. Comparison of local intravascular drug-delivery catheter systems. Am. Heart J. (1995) 130:1174–1181.
   PubMed Web of Science ®Google Scholar
• MARCH KL, WOODY M, MEHDI K, ZIPES DP, BRANTLY M, TRAPNELL BC: Efficient in vivo catheter-based pericar-dial gene transfer mediated by adenoviral vectors. Cardiol (1999) 22:123–129.
   Google Scholar
• LAMPING KG, RIOS CD, CHUN JA, 00BOSHI H, DAVIDSON BL, HEISTAD DD: Intrapericardial admini-stration of adenovirus for gene transfer. Am. J. Physiol (1997) 272:H310–H317.
   PubMed Web of Science ®Google Scholar
• MANN JM, DAVIES MJ: Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation (1996) 94:928–931.
   Google Scholar